GluBio Therapeutics

JAN 24, 2023

GluBio Therapeutics to Participate in Upcoming Molecular Glue Drug Development Summit

AUG 01, 2022

GluBio Therapeutics Completes Series A+ Financing of $22 Million to Advance the Development of Novel TPD Drugs

MAR 07, 2022

GluBio Therapeutics Raises Nearly $50 Million in Series A Round to Work on Molecular Glue Degraders

MAR 15, 2021

GluBio Therapeutics Announced the Closing of $20 Million Seed Financing Round from Three Founding Investors

MAR 01, 2021

GluBio Therapeutics Was Founded by Two Prominent Leaders in the Field of Targeted Protein Degradation